News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Merck & Co.
NEWS
JOBS
IN THE PRESS
AWARDS
NEWS
Biotech Bay
Newly Identified Rare Mutation Mimicked By Merck & Co.'s Zetia Cuts Heart Risk
November 14, 2014
·
1 min read
Biotech Bay
A Day Of Reckoning Approaches For Merck & Co. And Its Critics
November 14, 2014
·
1 min read
Drug Development
Confident Merck & Co. Expects No Writedowns For Zetia, Vytorin Cholesterol Drugs
November 11, 2014
·
2 min read
Drug Development
Merck & Co.'s Four-Week Hep C Regimen With Gilead Sciences, Inc.'s Sovaldi Fails To Deliver
November 10, 2014
·
2 min read
BioCapital
Bristol-Myers Squibb Company, Merck & Co. Competing Hodgkin’s Drugs Look Comparable, Says Analyst
November 6, 2014
·
1 min read
Drug Development
Merck & Co. Reports Positive Data From Phase 2b Doravirine Trial
November 3, 2014
·
1 min read
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson’s Studies
January 21, 2026
·
5 min read
Press Releases
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
January 20, 2026
·
63 min read
Press Releases
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
January 19, 2026
·
3 min read
Press Releases
Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
January 13, 2026
·
3 min read
Press Releases
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
January 13, 2026
·
6 min read
Press Releases
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
January 7, 2026
·
19 min read
Press Releases
Merck to Complete Acquisition of Cidara Therapeutics
January 7, 2026
·
6 min read
Press Releases
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
January 7, 2026
·
3 min read
Press Releases
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
3 min read
Press Releases
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
January 5, 2026
·
7 min read
